Vtama cream 1% effective, safe for intertriginous plaque psoriasis treatment
Click Here to Manage Email Alerts
Key takeaways:
- 82.8% of patients treated with Vtama achieved the primary endpoints at week 12.
- Vtama was well tolerated with no new safety signals.
New phase 4 study data showed Vtama cream 1% is effective and safe in the treatment of intertriginous plaque psoriasis in adults, Dermavant Sciences announced in a press release.
The results of this open-label, multi-center, phase 4 trial evaluating Vtama (tapinarof) cream 1% were presented at the 43rd Annual Fall Clinical Dermatology Conference held in Las Vegas.
“We are thrilled to share the impressive data from our phase 4 clinical trial of Vtama cream for the treatment of intertriginous plaque psoriasis (iPsO) in adult subjects,” Philip M. Brown, MD, JD, chief medical officer at Dermavant, said in the release. “The results show that Vtama cream is efficacious and well tolerated for the treatment of sensitive intertriginous areas, which is consistent with and builds upon our PSOARING phase 3 program.”
The trial consisted of 34 adults aged 18 or older with mild, moderate and severe iPsO. Each patient received Vtama cream once daily for 12 weeks and were evaluated 1 week post-treatment.
Results showed that 82.8% of patients treated with Vtama achieved the primary endpoints including an intertriginous-PGA (iPGA) score of 0 or 1 and a 2-grade or higher improvement from baseline at week 12.
According to the release, Vtama demonstrated a rapid onset of efficacy with a 6-week median time to iPGA success, with some achieving iPGA success as early as week 2. After a median of 8 weeks, 65.5% of patients reported complete disease clearance.
A proportion of patients experienced itch relief as early as week 1. Further, 50% achieved a 4-point or more improvement in itch by week 4 and 75% achieved this endpoint by the end of the study.
Vtama was well tolerated with no new safety signals, according to the release, with the most common adverse events being folliculitis, headache and contact dermatitis.